카페시타빈 시장 : 의약품 유형별, 적응증별, 최종사용자별, 국가별, 지역별 - 산업 분석, 시장 규모 및 점유율, 예측(2024-2032년)

REPORT HIGHLIGHT

Capecitabine Market size was valued at USD 415.9 Million in 2023, expanding at a CAGR of 5.50% from 2024 to 2032.

Capecitabine is an oral chemotherapy medication, which is used to treat a number of malignancies, such as those of the breast, colon, and rectal region. It is a member of the antimetabolite medication class, which inhibits the development and transmission of cancer cells. Since capecitabine is a prodrug, the body transforms it into 5-fluorouracil (5-FU), which is its active form. After being transformed, 5-FU stops cancer cells from making DNA and RNA, which eventually kills the cells. Capecitabine, which is typically given as pills, is taken orally as opposed to intravenously as conventional chemotherapy medications. The increase in the older population, the rise in cancer prevalence, and the intense research and development efforts to assess novel pharmacological uses of capecitabine are the main factors propelling the market's expansion. Additionally, the market is rising due to factors like the expansion of new cancer institutions, increased expenditure in cancer research, and others that are driving up demand for capecitabine. Furthermore, the market will rise even more during the projection period due to the growing development of new capecitabine product categories.

Capecitabine Market- Market Dynamics

Rising Incidence of Cancer

It is often necessary for the cancer cells to produce and fix DNA. As a result, cancer spreads to other body parts. In order to stop cancer cells from creating and repairing DNA, capecitabine must be used. One of the main factors propelling the use of capecitabine is the rising incidence of cancer, including lung, breast, and other forms, as well as the growing need for pharmaceutical research and development (R&D) for cancer therapy. For instance, the Global Cancer Observatory recently released data showing that 19,292,789 new cases of cancer were reported worldwide in 2020. With 11.7% of all cases, breast cancer was the most frequent type of cancer in 2020. Lung cancer came in second with 11.4%, colorectum cancer with 10%, prostate cancer with 7.3%, and stomach cancer with 5.6%. In order to stop cancer from spreading to important body parts, capecitabine is becoming more and more necessary as the number of cancer cases worldwide rises. Consequently, this is contributing to the expansion of the market.

Capecitabine Market- Key Insights

As per the analysis shared by our research analyst, the global Capecitabine Market is estimated to grow annually at a CAGR of around 5.50% over the forecast period (2024-2032)

Based on drug type segmentation, the branded category was predicted to show maximum Capecitabine Market share in the year 2023

Based on indication segmentation, the breast cancer was the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Capecitabine Market- Segmentation Analysis:

The Global Capecitabine Market is segmented on the basis of Drug Type, Indication, End-user, and Region.

The indication segment is divided into several categories, including Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Gastric Cancer, and Others. In 2023, the breast cancer segment held the largest market share in the capecitabine market. Healthcare facilities use capecitabine to treat breast cancer that has returned after prior treatment and has progressed to the lymph nodes and tissues surrounding the neck, chest, and other areas. Capecitabine is also used to treat triple-negative breast cancer in its early stages. For instance, in the male population of Europe, 2,339,617 new cases were detected. Breast cancer accounted for 12.07% of all cancer cases diagnosed in Europe in 2020, making it the most frequent kind. Therefore, the need for capecitabine to stop the spread of breast cancer is growing as the number of cases of the disease rises. The market is expanding as a result of this important element.

The end-user market is divided into various categories, such as Hospitals, Specialty Clinics, Homecare, and Others. The hospitals' segment held the largest market share in the capecitabine market in 2023. Several international governmental authorities, including the European Union and the US Food and Drug Administration (FDA), have approved the use of capecitabine. A key element of many cancer chemotherapy regimens is capecitabine. As a result, capecitabine is used in hospitals to treat a variety of cancers, such as colorectal cancer, advanced and metastatic breast cancer, and others.

Capecitabine Market- Geographical Insights

Geographically, the Capecitabine Market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

North America held the largest market share in the capecitabine industry in 2023. The rising incidence of cancer cases, the increased creation of new products, and other factors are blamed for this trend. For instance, the American Cancer Society estimates that between 800 and 900 new cases of osteosarcoma, a bone-affecting cancer, are discovered in the US annually, with half of those cases occurring in adolescents and teenagers. Consequently, the growing number of cancer cases in North America is supporting the expansion of the capecitabine market in the area.

In addition, the market for capecitabine is expanding quickly in Asia-Pacific due to the rising healthcare costs, expanded access to healthcare services, and rising cancer incidence rates. Oral chemotherapy medications like capecitabine are becoming more widely used in clinical practice as a result of governments and healthcare professionals in these areas realizing how important they are for enhancing patient convenience and treatment outcomes.

Capecitabine Market- Competitive Landscape:

The market for capecitabine is extremely competitive, with many major companies as well as a huge number of small and medium-sized businesses such as Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Mylan N.V., Pfizer Inc. (US), Sanofi (France), and others. These businesses have robust R&D capacities and a significant market presence due to their wide range of products and distribution systems. The market is notoriously competitive, with businesses concentrating on growing their product lines and gaining market share through partnerships, mergers, and acquisitions. For instance, the generic form of Xeloda (capecitabine) tablets was introduced in the US market in February 2021 by Dr. Reddy's Laboratories Ltd., an Indian company that manufactures the medication. Therefore, the capecitabine market is growing as a result of the increase in product offerings in the global market.

Recent Developments:

January 2023: For an undisclosed sum, Cheplapharm Arzneimittel GmbH, a pharmaceutical firm based in Germany, purchased the marketing rights to Xeloda (capecitabin) in China from F. Hoffmann-La Roche AG. Through the acquisition, Cheplapharma hopes to increase its market share in the pharmaceutical industry and fortify its cancer portfolio. The pharmaceutical business F. Hoffmann-La Roche AG, situated in Switzerland, manufactures the oral chemotherapy medication capecitabine, also known as Xeloda.

December 2022: A 90-second-dissolving Capecitabine dispersible pill for the treatment of colorectal and metastatic breast cancer was introduced by Shilpa Medicare. By increasing market revenue, the product's launch aids the corporation in diversifying its offerings.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CAPECITABINE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

• Teva Pharmaceutical Industries Ltd.(Israel)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Pfizer Inc. (US.)
• Sanofi (France)
• Bayer AG (Germany)
• Lilly (US.)
• Sun Pharmaceutical Industries Ltd. (India)
• GSK plc (UK.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (US.)
• Alkem Labs Ltd (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Others

GLOBAL CAPECITABINE MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

• Generic
• Branded

GLOBAL CAPECITABINE MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

• Breast Cancer
• Pancreatic Cancer
• Colorectal Cancer
• Gastric Cancer
• Others

GLOBAL CAPECITABINE MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

• Hospitals
• Specialty Clinics
• Homecare
• Others

GLOBAL CAPECITABINE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

• North America
• The US.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Capecitabine Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Capecitabine Market Snippet by Drug Type
  • 2.1.2. Capecitabine Market Snippet by Indication
  • 2.1.3. Capecitabine Market Snippet by End-user
  • 2.1.4. Capecitabine Market Snippet by Country
  • 2.1.5. Capecitabine Market Snippet by Region
• 2.2. Competitive Insights

3. Capecitabine Key Market Trends

• 3.1. Capecitabine Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Capecitabine Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Capecitabine Market Opportunities
• 3.4. Capecitabine Market Future Trends

4. Capecitabine Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Capecitabine Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Capecitabine Market Landscape

• 6.1. Capecitabine Market Share Analysis, 2023
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Capecitabine Market - By Drug Type

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
  • 7.1.2. Generic
  • 7.1.3. Branded

8. Capecitabine Market - By Indication

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
  • 8.1.2. Breast Cancer
  • 8.1.3. Pancreatic Cancer
  • 8.1.4. Colorectal Cancer
  • 8.1.5. Gastric Cancer
  • 8.1.6. Others

9. Capecitabine Market - By End-user

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By End-user, 2023 & 2032 (%)
  • 9.1.2. Hospitals
  • 9.1.3. Specialty Clinics
  • 9.1.4. Homecare
  • 9.1.5. Others

10. Capecitabine Market- By Geography

• 10.1. Introduction
  • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
• 10.2. North America
  • 10.2.1. Overview
  • 10.2.2. Capecitabine Key Manufacturers in North America
  • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  • 10.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.2.7. U.S.
    • 10.2.7.1. Overview
    • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.2.8. Canada
    • 10.2.8.1. Overview
    • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.2.8.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
• 10.3. Europe
  • 10.3.1. Overview
  • 10.3.2. Capecitabine Key Manufacturers in Europe
  • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  • 10.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3.7. Germany
    • 10.3.7.1. Overview
    • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.7.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3.8. France
    • 10.3.8.1. Overview
    • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.8.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.8.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.8.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3.9. Italy
    • 10.3.9.1. Overview
    • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.9.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.9.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.9.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3.10. Spain
    • 10.3.10.1. Overview
    • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.10.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.10.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.10.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3.11. United Kingdom
    • 10.3.11.1. Overview
    • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.11.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.11.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.11.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3.12. Russia
    • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.12.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.12.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.12.4. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3.13. Netherlands
    • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.13.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.13.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.13.4. Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3.14. Sweden
    • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.14.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.14.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.14.4. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3.15. Poland
    • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.15.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.15.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.15.4. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3.16. Rest of Europe
    • 10.3.16.1. Overview
    • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
• 10.4. Asia Pacific (APAC)
  • 10.4.1. Overview
  • 10.4.2. Capecitabine Key Manufacturers in Asia Pacific
  • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  • 10.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.4.6. Asia Pacific Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4.7. India
    • 10.4.7.1. Overview
    • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.7.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.7.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.7.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4.8. China
    • 10.4.8.1. Overview
    • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.8.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.8.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.8.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4.9. South Korea
    • 10.4.9.1. Overview
    • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.9.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.9.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.9.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4.10. Japan
    • 10.4.10.1. Overview
    • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.10.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.10.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.10.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4.11. Australia
    • 10.4.11.1. Overview
    • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.11.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4.12. Thailand
    • 10.4.12.1. Overview
    • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.12.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.12.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4.13. Indonesia
    • 10.4.13.1. Overview
    • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.13.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.13.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4.14. Philippines
    • 10.4.14.1. Overview
    • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4.15. Rest of APAC
    • 10.4.15.1. Overview
    • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
• 10.5. Latin America
  • 10.5.1. Overview
  • 10.5.2. Capecitabine Key Manufacturers in Latin America
  • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  • 10.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.5.6. Latin America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5.7. Brazil
    • 10.5.7.1. Overview
    • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5.8. Mexico
    • 10.5.8.1. Overview
    • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5.9. Argentina
    • 10.5.9.1. Overview
    • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5.10. Colombia
    • 10.5.10.1. Overview
    • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5.11. Rest of LATAM
    • 10.5.11.1. Overview
    • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
• 10.6. Middle East and Africa
  • 10.6.1. Overview
  • 10.6.2. Capecitabine Key Manufacturers in Middle East and Africa
  • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  • 10.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.6.6. Middle East and Africa Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6.7. Saudi Arabia
    • 10.6.7.1. Overview
    • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6.8. United Arab Emirates
    • 10.6.8.1. Overview
    • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6.9. Israel
    • 10.6.9.1. Overview
    • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.9.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6.10. Turkey
    • 10.6.10.1. Overview
    • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6.11. Algeria
    • 10.6.11.1. Overview
    • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6.12. Egypt
    • 10.6.12.1. Overview
    • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6.13. Rest of MEA
    • 10.6.13.1. Overview
    • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Capecitabine Industry

• 11.1. Competitive Dashboard
• 11.2. Company Profiles
  • 11.2.1. Teva Pharmaceutical Industries Ltd.(Israel)
  • 11.2.2. F. Hoffmann-La Roche Ltd. (Switzerland)
  • 11.2.3. Mylan N.V. (U.S.)
  • 11.2.4. Pfizer Inc. (US.)
  • 11.2.5. Sanofi (France)
  • 11.2.6. Bayer AG (Germany)
  • 11.2.7. Lilly (US.)
  • 11.2.8. Sun Pharmaceutical Industries Ltd. (India)
  • 11.2.9. GSK plc (UK.)
  • 11.2.10. Novartis AG (Switzerland)
  • 11.2.11. Merck & Co., Inc. (US.)
  • 11.2.12. Alkem Labs Ltd (India)
  • 11.2.13. Aurobindo Pharma (India)
  • 11.2.14. Lupin (India)
  • 11.2.15. Others

12. 360 Degree Analyst View

13. Appendix

• 13.1. Research Methodology
• 13.2. References
• 13.3. Abbreviations
• 13.4. Disclaimer
• 13.5. Contact Us